The short answer
Manufacturers do not have a universal chromatographic trick that cleanly separates every deletion peptide or epimer: they combine prevention, impurity-specific analytical methods, optimized purification selectivity, and sometimes substantial recovery sacrifice.[1,2] Near-quantitative coupling is achieved through sequence-aware chemistry, accessible resin-bound chains, monitoring, and corrective operations—not merely by choosing a powerful coupling reagent.[3] Oxazolone formation is one stereochemical failure pathway, but direct α-proton abstraction and residue-specific chemistry make His and Cys particularly important challenges under some conditions.[6,8,9] I cannot infer our suppliers' epimerization risk without their actual reagent, base, protection, activation-time, temperature, and process-control information. For Peptide Partners, a convincing purity claim must connect the manufacturing failure map to demonstrated analytical selectivity, rather than equate a single large UV peak with correct sequence and stereochemistry.
The yield calculation is harsher—and more nuanced—than the slogan
For an idealized 39-residue peptide assembled from one preloaded residue, there are 38 chain-extension couplings. If each has independent probability p of making the correct extension and every failure survives as an incorrect chain, the correct-chain fraction is p^38. This is my deliberately simplified model, not a reported Retatrutide manufacturing yield. It ignores loading, deprotection, side reactions, cleavage, conjugation, and purification.
| Correct extension per coupling | Correct chains after 38 couplings |
|---|---|
| 98.0% | 46.4% |
| 99.0% | 68.3% |
| 99.5% | 82.7% |
| 99.8% | 92.7% |
| 99.9% | 96.3% |
Thus 99.5% is not a mathematical threshold required to obtain any usable long peptide. It is a demanding performance target that still permits a substantial incorrect-chain population. The CHEM202L notes' compounding argument is right; the fuller picture is that coupling conversion, correct-sequence fraction, crude chromatographic purity, and isolated yield are four different quantities. A near-complete reaction may incorporate an epimer efficiently, producing high conversion and poor chemical correctness.
Counting additional operations makes the distinction more important. In my hypothetical process with 77 independent fidelity-critical operations each succeeding at 99.5%, the all-correct fraction is only 0.995^77 = 68.0%. Real steps are neither equally difficult nor independent: aggregation can cause correlated failures at particular sequence positions. Averaging easy and hard couplings can conceal the bottleneck that generates most of the final impurity burden.
At a 0.5% failure probability per extension, the idealized probability of exactly one failed extension is 38 × 0.005 × 0.995^37 = 15.8%. Each position contributes roughly 0.415% of chains if all positions behave identically. These are illustrative probabilities before any selective removal, not predictions of thirty-eight equal impurity peaks. They show why a chromatogram may contain a distributed family of closely related species rather than one conspicuous failed product.
Map the impurity to the operation that created it
A deletion sequence lacks a residue but may otherwise resume normal chain extension. Failed coupling leaves an unreacted amine that can accept the next residue; incomplete Fmoc removal can similarly cause a position to be skipped when a later deprotection succeeds. A truncation is a prematurely terminated chain, frequently missing an N-terminal segment in ordinary C-to-N SPPS. These labels overlap in informal use, so an impurity register should record the actual structure rather than rely on the word “shortmer.”[1,2]
An insertion contains an extra residue. It can originate in protected-dipeptide contamination of an amino-acid building block or inappropriate loss of N-protection during coupling; simply adding excess correctly protected monomer does not automatically insert two residues.[1] Substitutions may derive from raw-material contamination or carryover, while side-chain protection remnants, unintended acylation, oxidation, and oligomers expand the impurity family.[1,2] “The expected molecular weight appeared” is not a characterization of this entire distribution.
Capping deliberately terminates unreacted chains after an incomplete coupling, commonly by acylating residual amines. It converts some future deletion sequences into terminated, often more distinguishable impurities instead of repairing them. The tradeoff is loss of recoverable target precursor, and a protected amine left by incomplete deprotection may evade an amine-directed cap. I would ask which failure modes capping actually intercepts and how the cap-derived products are purged, not treat capping as proof that deletions are impossible.[1,3]
┌────────────────────────┐
│ ACCESSIBLE GROWING CHAIN│
└────────────┬───────────┘
│ DEPROTECT → COUPLE
├──→ CORRECT EXTENSION → NEXT CYCLE
│
├──→ FREE AMINE REMAINS
│ ├──→ RECOUPLE → POSSIBLE RESCUE
│ ├──→ CAP ────→ TERMINATED IMPURITY
│ └──→ NEXT RESIDUE → DELETION SEQUENCE
│
└──→ ACTIVATED RESIDUE EPIMERIZES
└──→ EFFICIENT COUPLING OF WRONG STEREOISOMER
↓
SAME MASS, DIFFERENT PEPTIDE
This map separates reaction conversion from product identity. It also explains why a negative residual-amine test does not prove a correct sequence or preserved stereochemistry. The assay may show that accessible amines reacted while missing inaccessible sites, protected sites, or the identity of the installed residue. I want in-process controls whose limitations are understood, with representative cleavage/LC characterization at the positions that actually drive risk.[3]
How manufacturers keep difficult chains reactive
Aggregation on resin can make nominally available reactive sites physically inaccessible. Growing chains can form hydrogen-bonded structures, making deprotection and coupling heterogeneous. Behrendt, White, and Offer discuss the sequence-dependent limitations and improvements in Fmoc SPPS; this is not a simple “increase equivalents until complete” problem.[3] My inference is that resin loading, swelling, solvent choice, mixing, and chain conformation belong in the same troubleshooting conversation as coupling-reagent identity.
A useful preventive strategy is to disrupt the backbone's tendency to associate. Pseudoproline building blocks temporarily convert suitable Ser/Thr-derived motifs into cyclic structures that disrupt secondary structure during assembly; Wöhr and colleagues reported improved solvation and coupling behavior from this structure-disrupting protection strategy.[4] Their utility is sequence- and protection-strategy-dependent, not an available substitution at every residue. The intended native structure must be regenerated and verified after removal of the temporary protection.
Backbone protection, including Hmb/Dmb-type approaches discussed in the Fmoc synthesis literature, also interrupts backbone hydrogen bonding.[3] It can help difficult sequences and some side reactions, but adds its own installation, coupling, and removal constraints. Double coupling, fresh reagents, monitored deprotection, and optimized temperature can help other bottlenecks. Increasing reaction time or temperature indiscriminately can instead give a problematic activated residue more opportunity to epimerize.
Industrial success therefore requires a sequence-specific process, with incoming building-block controls and evidence that washing, deprotection, coupling, and cleavage remain reproducible at scale. A small development experiment does not automatically transfer to a swollen resin bed with different mixing and heat transfer. I would ask for demonstrated ranges and impurity trends, not confidential recipes for their own sake. The important evidence is that deviations have known consequences and that controls prevent or detect those consequences.
Fragment routes change the problem rather than abolish it
In hybrid SPPS/LPPS, shorter fragments are assembled on solid support, qualified or purified, then joined in solution. Frederick and colleagues reported kilogram-scale GMP manufacture of Tirzepatide using a hybrid approach, continuous operations, real-time analytical monitoring, and nanofiltration for intermediate purification.[5] This is a documented industrial precedent, not evidence that any particular Retatrutide supplier uses the same route. I must keep those molecules and manufacturing claims separate.
A nine-coupling fragment at 99.5% idealized per-step fidelity has a correct-chain fraction of 95.6%, making intermediate characterization and cleanup more tractable than waiting until a complete long chain is assembled. But multiplying four such unpurified fractions still gives only about 83.5% before joining losses. The advantage is the opportunity to remove impurities, avoid the worst long-chain aggregation, and optimize fragment interfaces—not escape from multiplication. Fragment condensation also activates a peptide C-terminus and can create its own epimerization risk, so junction choice and stereochemical control are central.[3,9]
Racemization is not just a little SN1 chemistry
CHEM201's planar-intermediate intuition is useful, but peptide coupling normally proceeds by nucleophilic acyl substitution, not through a freely rotating α-carbon carbocation. The stereocenter becomes vulnerable when its α-proton is removed or when an activated derivative cyclizes into an intermediate that facilitates that removal. Strictly, inversion at one center of an otherwise chiral peptide creates an epimeric diastereomer rather than a complete enantiomeric racemate. The synthetic literature often uses “racemization” as the practical umbrella term.[9]
The principal mechanistic routes are:
- Oxazolone-mediated epimerization: activation of an appropriate N-acyl amino-acid or peptide carboxyl terminus allows cyclization to an oxazolone. Removal and return of the α-proton can erase and reset its configuration before productive coupling.
- Direct enolization/α-proton abstraction: an activated amino-acid derivative can lose its α-proton under basic conditions without needing that cyclic intermediate. Reprotonation can produce the unwanted configuration.
- Residue- and protection-specific acceleration: side-chain electronics and intramolecular catalysis alter susceptibility, so the same nominal reagent system can behave differently for different residues and protecting groups.[6,8,9]
I would not assert that every Fmoc-amino-acid coupling is dominated by oxazolone formation. N-protection, whether the activated species is an amino-acid derivative or a peptide fragment, and the competition between activation, coupling, and proton exchange all matter. His is problematic because of its imidazole-related chemistry; Cys is a recognized high-risk residue whose protection and coupling conditions materially affect epimerization.[6,8] Aib, by contrast, has no α-hydrogen and no α-stereocenter, although its steric demands may complicate coupling.
Han, Albericio, and Barany provide a caution against reassuring reagent labels. In their specific cysteine model, conventional phosphonium/aminium-reagent protocols with preactivation and tertiary base produced D:L product ratios of 5–33%; avoiding preactivation markedly reduced those values.[6] Those figures are not an estimate of today's supplier batches, and D:L ratios are not numerically identical to percent D in total product. The study establishes sensitivity to conditions and protecting groups, not universal condemnation of HATU.
Oxyma/DIC versus HATU/DIPEA is a comparison to test
Oxyma was introduced as a carbodiimide-coupling additive with useful coupling efficiency and suppression of racemization in tested models.[7] DIC/Oxyma can often be implemented without the large tertiary-base burden of a HATU/DIPEA system. That makes it an important candidate, not a guarantee of stereochemical purity. Oxyma is an additive and DIC an activator; their concentrations, order of contact, solvent, temperature, and residence times remain part of the chemistry.
HATU/DIPEA can provide rapid productive coupling, which may help by shortening the lifetime of a vulnerable activated species, while added base and slow consumption can work in the opposite direction. The relevant competition is between productive capture and side reaction, not “fast reagent good” or “base bad.” My inference is that the best process minimizes the integrated exposure of the activated vulnerable residue while maintaining conversion and control of other by-products. I would not prescribe either system without comparative impurity data.
Yang, Hansen, and Baldi's histidine study makes this conflict concrete. Their design-of-experiments work found that more intensive Fmoc-His(Trt)-OH preactivation promoted racemization, while omitting preactivation increased DIC-derived Nα endcapping; the two problems had to be balanced.[8] The His epimer was not effectively purged by their applied chromatographic purification. This is stronger evidence for prevention than any generic claim that preparative HPLC can always clean up the chemistry.
What purification can realistically achieve
If target and impurity have identical selectivity under a chosen condition, increasing column length is not a cure. In the approximate isocratic plate model, resolution scales with √N × [(α−1)/α] × [k/(1+k)]; at α = 1, the selectivity term is zero. This is my application of chromatographic theory, not a literal design equation for overloaded preparative peptide gradients. Doubling efficiency gives only a square-root gain even when selectivity is nonzero.
I would screen stationary-phase chemistry, pH within peptide/column stability limits, ion-pairing conditions, temperature, and gradient shape to change relative retention. Ion-exchange, mixed-mode, or other orthogonal separations may distinguish species whose reversed-phase behavior is nearly identical; USP explicitly discusses alternatives to a single RP-HPLC method.[1] Lower preparative loading and tighter fraction cuts can improve collected purity while losing target recovery. Any reported recovery must therefore accompany its impurity endpoint.
A practical development sequence is to identify the critical impurity pair, demonstrate an analytical separation or selective quantifier, and then establish preparative fraction behavior under real loading. Fraction testing must not reuse a method that already hides the critical impurity. Pooling decisions should account for tails and carryover as well as the attractive center fraction. If selectivity remains inadequate, changing synthesis or fragment strategy is more credible than repeatedly polishing the same unresolved mixture.
Detecting what purification may leave behind
High-resolution LC-MS/MS is powerful for deletion sequences because loss of a residue changes neutral mass and, with sufficient fragmentation coverage, can be localized. A glycine deletion changes residue mass by approximately 57.0215 Da; at charge +5, the corresponding same-charge m/z difference is about 11.4043. These are calculated mass differences, not measured PP results. Repeated residues can make positional assignment ambiguous, so intact mass alone does not identify which glycine was lost.
Kodidasu and colleagues developed calibrated HRMS methods for coeluting des-Gly4 and des-Thr5 glucagon impurities, reporting quantitation limits of 0.02% and 0.04%, respectively, in their methods.[13] This demonstrates that mass-selective quantitation can work even when UV separation fails. It does not justify treating uncalibrated MS intensity as impurity percentage in every peptide: their performance depended on specific methods and validation. Our own impurity standards, matrix effects, response, and sensitivity must be established.
Chiral amino acid analysis asks a different question. Acid hydrolysis releases residues, and Marfey's reagent converts amino-acid enantiomers into separable diastereomeric derivatives for appropriate chromatographic analysis.[10] The method can reveal D/L composition but generally loses the residue's original position in the peptide. If four identical residues are present, detection of a D component does not alone locate which position changed or establish a unique intact-peptide impurity concentration.
Hydrolysis and derivatization can themselves create epimerization. USP 〈1503〉 describes use of DCl/D₂O so α-hydrogen/deuterium exchange accompanying analytical epimerization can be distinguished with MS-based detection and used for correction.[1] This requires validation of isotope exchange, recoveries, and stereochemical separation; it is not a promise that deuterated acid makes hydrolysis nonracemizing. Standards carried through the entire preparation are more informative than standards injected only after hydrolysis.
Broberg and colleagues demonstrated a particularly instructive hydrolysis artifact involving 3-hydroxyvaline-containing peptides and proposed inter-residue oxazoline chemistry.[11] That specialized mechanism should not be generalized to every therapeutic peptide, but it proves that sample preparation can alter the very stereochemistry being investigated. I would combine corrected chiral analysis with targeted intact-peptide epimer standards where feasible. Agreement between independent approaches is more persuasive than a single “no D-amino acids detected” line without limits or artifact controls.
What the FDA's 2021 guidance actually says
FDA's final 2021 guidance concerns ANDAs for certain highly purified synthetic peptides referencing rDNA-origin products: glucagon, liraglutide, nesiritide, teriparatide, and teduglutide.[12] It is not a universal specification for every peptide, a Retatrutide authorization, or an RUO release standard. It addresses when reliance on the ANDA pathway may be appropriate, including comparative impurity and immunogenicity considerations.
For peptide-related impurities shared with the reference listed drug, the proposed generic's level should be the same or lower. The framework generally expects no new specified peptide-related impurity above 0.5% of drug substance, with characterization and justification of new specified impurities rather than automatic acceptance below that ceiling.[12] FDA generally recommends identifying each peptide-related impurity at 0.10% or greater, and may ask for identification below that level depending on risk. In this context, identification means structural characterization, not merely naming a chromatographic peak “unknown 3.”
These percentages are not a universal “99.5% pure is safe” rule. A total impurity figure and the maximum level of an individual new impurity answer different questions, and FDA can request further reduction or evidence. The guidance recommends sensitive, high-resolution analytical procedures and comparative assessment; a new 0.3% impurity is not automatically qualified.[12] I take the scientific lesson—identify the species and justify the evidence—without implying PP's research materials meet clinical product standards.
What this means for Peptide Partners
I would build a supplier-specific impurity risk map connecting sequence positions, building blocks, coupling/deprotection stresses, conjugation or fragment junctions, and likely impurities. For each critical species, the map should record whether the release method resolves it, selectively quantifies it, or remains blind. Raw-material stereopurity and process controls deserve as much attention as the final chromatogram. This is a proposed PP quality practice informed by USP's process-linked control strategy, not a claim that we already possess these records.[1]
Larissa's lab should be able to distinguish target identity, related-substances purity, and chiral integrity. I would prioritize an orthogonal LC method, access to HRMS/MS, qualified impurity standards for the worst pairs, and a defensible external or internal chiral-analysis workflow. Supplier CoAs should disclose unresolved critical impurities and method limits rather than equate “MS correct” with “sequence and stereochemistry fully verified.” We should compare purification recovery and impurity clearance together when deciding whether a route is genuinely robust.
Questions to bring to the lab
- Which specific deletions or epimers coelute under each supplier's release method, and do we have standards proving that claim?
- What fraction of reported “per-step yield” is correct incorporation rather than conversion, and how are deprotection failures counted?
- Where are aggregation-prone positions, and what evidence supports resin loading, backbone protection, or pseudoproline choices there?
- For every His/Cys-containing product, what do preactivation time, base exposure, temperature excursions, and protection choices do to the impurity profile?
- Does capping prevent our dominant deletions, or mostly create a different truncation burden that is easier to measure?
- Can our chiral assay distinguish pre-existing epimers from hydrolysis/derivatization artifacts, including repeat-residue and noncanonical-residue complications?
- When preparative selectivity fails, what is the measured recovery penalty, and would an upstream or fragment-route change be more effective?
What I still don't know
I do not have our suppliers' route descriptions, intermediate impurity profiles, or actual stereochemical-control data. Published Tirzepatide manufacturing does not reveal proprietary Retatrutide routes, and generic model-peptide racemization percentages cannot be assigned to an unknown supplier process. High confidence here applies to the measurement and chemistry framework, not to an estimate of PP's present lot quality.
I also do not know whether routine hydrolysate chiral analysis can resolve and recover every noncanonical residue in our portfolio, or which positional epimers require custom standards. Those are method-development questions. Until the critical impurity pairs and analytical blind spots are experimentally mapped, “greater than 99% by HPLC” remains a narrower statement than “the intended peptide is chemically correct.”
References
- United States Pharmacopeia. 〈1503〉 Quality Attributes of Synthetic Peptide Drug Substances. USP–NF. 2021. Rockville, MD: United States Pharmacopeia. doi:10.31003/USPNF_M12935_02_01
- D’Hondt M, Bracke N, Taevernier L et al. Related impurities in peptide medicines. Journal of Pharmaceutical and Biomedical Analysis. 2014;101:2-30. doi:10.1016/j.jpba.2014.06.012
- Behrendt R, White P, Offer J. Advances in Fmoc solid‐phase peptide synthesis. Journal of Peptide Science. 2016;22(1):4-27. doi:10.1002/psc.2836
- Wöhr T, Wahl F, Nefzi A et al. Pseudo-Prolines as a Solubilizing, Structure-Disrupting Protection Technique in Peptide Synthesis. Journal of the American Chemical Society. 1996;118(39):9218-9227. doi:10.1021/ja961509q
- Frederick MO, Boyse RA, Braden TM et al. Kilogram-Scale GMP Manufacture of Tirzepatide Using a Hybrid SPPS/LPPS Approach with Continuous Manufacturing. Organic Process Research & Development. 2021;25(7):1628-1636. doi:10.1021/acs.oprd.1c00108
- Han Y, Albericio F, Barany G. Occurrence and Minimization of Cysteine Racemization during Stepwise Solid-Phase Peptide Synthesis1,2. The Journal of Organic Chemistry. 1997;62(13):4307-4312. doi:10.1021/jo9622744
- Subirós-Funosas R, Prohens R, Barbas R et al. Oxyma: an efficient additive for peptide synthesis to replace the benzotriazole-based HOBt and HOAt with a lower risk of explosion. Chemistry (Weinheim an der Bergstrasse, Germany). 2009;15(37):9394-9403. doi:10.1002/chem.200900614
- Yang Y, Hansen L, Baldi A. Suppression of Simultaneous Fmoc-His(Trt)-OH Racemization and Nα-DIC-Endcapping in Solid-Phase Peptide Synthesis through Design of Experiments and Its Implication for an Amino Acid Activation Strategy in Peptide Synthesis. Organic Process Research & Development. 2022;26(8):2464-2474. doi:10.1021/acs.oprd.2c00144
- Duengo S, Muhajir MI, Hidayat AT et al. Epimerisation in Peptide Synthesis. Molecules. 2023;28(24):8017. doi:10.3390/molecules28248017
- Bhushan R, Brückner H. Marfey's reagent for chiral amino acid analysis: a review. Amino acids. 2004;27(3-4):231-247. doi:10.1007/s00726-004-0118-0
- Broberg A, Nord C, Levenfors JJ et al. In-peptide amino acid racemization via inter-residue oxazoline intermediates during acidic hydrolysis. Amino Acids. 2021;53(3):323-331. doi:10.1007/s00726-021-02951-7
- U.S. Food and Drug Administration. ANDAs for Certain Highly Purified Synthetic Peptide Drug Products That Refer to Listed Drugs of rDNA Origin. Guidance for Industry. May 2021. NLM-hosted agency document; full text.
- Kodidasu A, Acharyya K, Ramu VG. Absolute Quantitation of Coeluting Impurities in Peptide Drugs Using High Resolution Mass Spectrometry: Glucagon a Case Study in Pharmaceutical Development. Journal of the American Society for Mass Spectrometry. 2025;36(10):2072-2078. doi:10.1021/jasms.5c00105